An update from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) is now available.
Biocytogen Pharmaceuticals has announced its preliminary financial results for the year 2024, indicating a significant turnaround from a loss to a profit. The company’s revenue is expected to increase by approximately 35.8% to 37.2% compared to the previous year, with a reduction in research and development expenses by around 30.7% to 32.8%. This growth is attributed to increased recognition of its antibody discovery business and rapid expansion in its gene editing animal model business, particularly in overseas markets. Strategic adjustments have also contributed to this positive performance, with a focus on cost control and operational efficiency.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a pharmaceutical company based in China, specializing in antibody discovery and gene editing animal models. The company has a strong focus on expanding its presence in overseas markets, particularly in the antibody discovery sector.
YTD Price Performance: -2.24%
Average Trading Volume: 99,930
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$3.22B
Learn more about 2315 stock on TipRanks’ Stock Analysis page.